Compare BH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | MGTX |
|---|---|---|
| Founded | 1934 | 2015 |
| Country | United States | United States |
| Employees | 2359 | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 909.1M |
| IPO Year | N/A | 2018 |
| Metric | BH | MGTX |
|---|---|---|
| Price | $409.70 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 49.8K | ★ 1.0M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $234.92 | $6.62 |
| 52 Week High | $483.60 | $13.94 |
| Indicator | BH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 77.30 | 74.69 |
| Support Level | $299.20 | $7.10 |
| Resistance Level | $421.66 | N/A |
| Average True Range (ATR) | 21.54 | 0.74 |
| MACD | 8.57 | 0.32 |
| Stochastic Oscillator | 81.31 | 99.55 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.